PolyPid Ltd.
Industry
- Pharmaceuticals
- Specialty Pharmaceuticals
- Drug Delivery
- Controlled Release
- Site Specific
- Medical Devices
- Biomaterials
- Biotechnology
Latest on PolyPid Ltd.
Following a missed Phase III endpoint in 2022 , PolyPid has reported positive top-line results from its Phase III SHIELD II trial with D-PLEX100 for the prevention of surgical site infections (SSIs)
The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’
Many public biopharmaceutical companies have turned to alternatives other than follow-on public offerings (FOPOs) this year to fund their research and development programs while stock prices have been